Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07428499 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
A Phase 3 study, sponsored by ADARx Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT07428499: Recruiting Phase 3 study, sponsored by ADARx Pharmaceuticals.
NCT07428499 is a Phase 3 study that is actively recruiting participants, run by ADARx Pharmaceuticals. The registered enrollment target is 90 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07428499, a Phase 3 study, is actively recruiting participants, sponsored by ADARx Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Primary Outcome
Incidence and severity of treatment-emergent adverse events
Interventions
- DRUG ADX-324 Dose Level 1
- DRUG ADX-324 Dose Level 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-04-02 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 3 |
What NCT07428499 shows while recruiting
NCT07428499 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which ADX-324 Dose Level 1 is the first listed.
NCT07428499 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07428499 about?
NCT07428499 is a clinical study titled "Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)". Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also inc...
What is the current status of trial NCT07428499?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2026-04-02. Estimated completion is 2030-06-30.
What interventions are being tested in trial NCT07428499?
The interventions under investigation include: ADX-324 Dose Level 1 (DRUG), ADX-324 Dose Level 2 (DRUG).
Who is sponsoring clinical trial NCT07428499?
This trial is sponsored by ADARx Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07428499's enrollment target sits among peer trials
90 1724th of 2000 higher than 263 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI